Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

ClinicalTrials.gov ID: NCT01515007

Public ClinicalTrials.gov record NCT01515007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3)

Study identification

NCT ID
NCT01515007
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Aradigm Corporation
Industry
Enrollment
278 participants

Conditions and interventions

Interventions

  • Ciprofloxacin dispersion for inhalation Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 30, 2014
Primary completion
Aug 16, 2016
Completion
Sep 30, 2016
Last update posted
Mar 25, 2021

2014 – 2016

United States locations

U.S. sites
30
U.S. states
18
U.S. cities
30
Facility City State ZIP Site status
Not listed Peoria Arizona
Not listed Phoenix Arizona
Not listed Downey California
Not listed Los Angeles California
Not listed Poway California
Not listed Farmington Connecticut
Not listed Washington D.C. District of Columbia
Not listed Celebration Florida
Not listed Kissimmee Florida
Not listed Miami Florida
Not listed Sebring Florida
Not listed Kailua Hawaii
Not listed Chicago Illinois
Not listed Columbia Maryland
Not listed Royal Oak Michigan
Not listed Rochester Minnesota
Not listed Lincoln Nebraska
Not listed Cedar Knolls New Jersey
Not listed New Hyde Park New York
Not listed New York New York
Not listed Syracuse New York
Not listed Charlotte North Carolina
Not listed Huntersville North Carolina
Not listed Oklahoma City Oklahoma
Not listed Anderson South Carolina
Not listed Charleston South Carolina
Not listed Columbia South Carolina
Not listed Fort Worth Texas
Not listed Tyler Texas
Not listed Falls Church Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01515007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 25, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01515007 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →